Background: Previous studies showed that patients with Severe IBS respond better to fecal microbiota transplantation (FMT) than do those with Moderate IBS.
Aims: The present study aimed to determine the effects of the transplant dose, route of administering it and repeating FMT on this difference.
Methods: This study included 186 patients with IBS randomized 1:1:1 into groups with a 90-g transplant administered once to the colon (LI), once to the duodenum (SI), or twice to the distal duodenum twice (repeated SI). The patients provided a fecal sample and were asked to complete three questionnaires at baseline and at 3, 6, and 12 months after FMT. The fecal bacteria composition and Dysbiosis index were analyzed using 16 S rRNA gene PCR DNA amplification/probe hybridization covering regions V3-V9.
Results: There was no difference in the response rates between severe IBS and moderate IBS for SI and repeated SI at all observation intervals after FMT. In the LI group, the response rate at 3 months after FMT was higher for moderate IBS than for severe IBS. The levels of Dorea spp. were higher and those of Streptococcus salivarius subsp. Thermophilus, Alistipes spp., Bacteroides and Prevotella spp., Parabacteroides johnsoni and Parabacteroides spp. were lower in moderate IBS than in severe IBS.
Conclusions: There was no difference in the response to FMT between severe and moderate IBS when a 90-g transplant was administered to the small intestine. The difference in the bacterial profile between severe and moderate IBS may explain the difference in symptoms between these patients. ( www.
Clinicaltrials: gov : NCT04236843).
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11026185 | PMC |
http://dx.doi.org/10.1007/s10620-024-08369-x | DOI Listing |
Actas Dermosifiliogr
January 2025
Dermatology, University Hospital, Coimbra Local Health Unit, Coimbra, Portugal; Faculty of Medicine, University of Coimbra, Coimbra, Portugal.
Introduction: Dupilumab is an IL-4 / IL-13 inhibitor monoclonal antibody approved for the treatment of moderate-to-severe atopic dermatitis (AD) with remarkable safety and efficacy profiles. However, former studies have reported an increase in serum eosinophils during treatment, with undetermined clinical significance.
The Objective: of this study is to evaluate changes in blood eosinophils and other laboratory parameters while on dupilumab.
Neurogastroenterol Motil
January 2025
Faculty of Medicine, Centre for Health Services Research, Centre for Online Health, The University of Queensland, Woolloongabba, Queensland, Australia.
Ear Hear
January 2025
Department of Otolaryngology, University Hospital Regensburg, Regensburg, Germany.
Objectives: Hearing aids (HAs) are a widely accepted first-line treatment option for individuals suffering from both hearing loss and chronic tinnitus. Though HAs are highly effective at improving speech understanding, their effectiveness in ameliorating tinnitus symptoms is less clear. In recent years, several investigators have reported on attempts to predict HAs effectiveness on tinnitus symptoms using an array of variables.
View Article and Find Full Text PDFActas Dermosifiliogr
December 2024
Servicio de Dermatología, Hospital Universitario San Cecilio, Granada. Instituto Biosanitario de Granada (ibs.GRANADA), Spain. Electronic address:
Gels
November 2024
Electro-Medical Equipment Research Division, Korea Electrotechnology Research Institute (KERI), Ansan 15588, Republic of Korea.
Shape-memory materials are widely utilized in biomedical devices and tissue engineering, particularly for their ability to undergo predefined shape changes in response to external stimuli. In this study, a shape-transformable organohydrogel was developed by incorporating a gallium mesh into a polyacrylamide/alginate/glycerol matrix. The gallium mesh, which transitions between solid and liquid states at moderate temperatures (~29.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!